Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies
出版年份 2018 全文链接
标题
Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies
作者
关键词
Radiation therapy, Non-small cell lung cancer, Cancer treatment, Brain metastasis, Lung and intrathoracic tumors, Meta-analysis, Brain diseases, Lesions
出版物
PLoS One
Volume 13, Issue 7, Pages e0201425
出版商
Public Library of Science (PLoS)
发表日期
2018-07-28
DOI
10.1371/journal.pone.0201425
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Real-World Clinical Outcomes of Crizotinib Treatment in ALK-Positive Non–Small Cell Lung Cancer Patients with Brain Metastases
- (2017) K.L. Davis et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP
- (2017) Tomohide Tamura et al. JOURNAL OF CLINICAL ONCOLOGY
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
- (2017) Dong-Wan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer
- (2017) Mark K. Doherty et al. RADIOTHERAPY AND ONCOLOGY
- Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer
- (2017) Xiangchan Hong et al. Oncotarget
- The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
- (2016) Sen Zhang et al. CLINICAL CANCER RESEARCH
- Extended Survival and Prognostic Factors for Patients WithALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis
- (2016) Kimberly L. Johung et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer
- (2016) Shirish M. Gadgeel et al. JOURNAL OF CLINICAL ONCOLOGY
- Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014
- (2016) Benjamin J. Solomon et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients WithALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
- (2016) Lucio Crinò et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib’s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series
- (2016) Giulio Metro et al. JOURNAL OF NEURO-ONCOLOGY
- Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
- (2016) Scott N Gettinger et al. LANCET ONCOLOGY
- Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- (2016) Dong-Wan Kim et al. LANCET ONCOLOGY
- Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer
- (2016) Tatsuya Yoshida et al. LUNG CANCER
- Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases
- (2016) Puyuan Xing et al. Oncotarget
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
- (2015) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
- (2015) Justin F. Gainor et al. Journal of Thoracic Oncology
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
- (2015) Deepa Rangachari et al. LUNG CANCER
- Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)
- (2015) Anita Kort et al. PHARMACOLOGICAL RESEARCH
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- A basic introduction to fixed-effect and random-effects models for meta-analysis
- (2010) Michael Borenstein et al. Research Synthesis Methods
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now